Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company's new digital strategy, led by the company's recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG's social media platforms.
The various analytical markers all showed uplifts, in some cases there was an increase of over 500%.
Digital strategies, such as GTG's approach, are leveraging the growing awareness of the importance and utility of understanding a person's individual risk of developing a range of diseases. Know your risk and you and your doctor can take steps to diagnose disease early significantly improving health outcomes.
GTG predicts a significant surge in the adoption of risk assessment tests, driven by both patients and doctors. The company sees its geneType digital strategy as spearheading a transformative shift from "sickcare" to genuine "healthcare". This transformation is echoed by leading breast specialist, Dr. Nicole Yap, who emphasizes the importance of early detection in breast cancer. Dr. Yap's sentiments are reinforced by the Australian Breast Care Centre, dedicated to raising awareness about breast cancer risk assessment.
GTG's approach has garnered substantial interest, evident in the increasing number of healthcare professionals referring patients to their services. Monthly, the company receives commercial samples from new providers across Australia and the US, indicating a growing clinician referral base. In the US, GTG regularly receives samples from over 10 states, with new providers joining each month.
"If you knew you are at moderate to high risk of up to seven potentially fatal cancers, coronary artery disease, atrial fibrillation or type II diabetes you should be very highly motivated to find ways to reduce your risk and prevent disease," said GTG's CEO Simon Morriss.
Approved by the Chairman of the Board of Directors.
Posted In: GENE